HALIFAX, Oct. 21, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, has received an
additional USD $1.917 million from the US Army. The Company is
currently developing and commercializing two rapid tests for
transfusion transmitted diseases under a United States Army Medical
Research Acquisition Activity (USAMRAA) contract.
The new funding enables MedMira to conduct additional testing for the
Reveal Rapid Hepatitis B Surface Antigen Test and Multiplo Rapid
HBc/HIV/HCV Antibody Test in parallel with the current clinical trials.
Testing of additional specimens will provide the clinical data required
for MedMira to obtain complementary label claims and intended uses for
these two products, expanding their utility in a number of field
"The additional product testing that we can now perform on the Reveal
and Multiplo products will allow our customers access to powerful
diagnostic capabilities in a wider range of environments and
situations," said Kevin Jones, Senior Director, Global Sales &
Marketing, MedMira. "The end result of the additional funding will be
that more tests will be performed at a faster rate and a lower cost
than has previously been attainable. The benefits for patients and
healthcare providers using rapid tests built on our technology
platform, especially the Multiplo triple test, will be seen not just in
the US, but by organizations across the globe."
MedMira foresees that the new testing will demonstrate that the Reveal
and Multiplo products are suitable for additional uses beyond the
original areas of interest on the frontlines of military healthcare in
emergency medical situations and for screening transfusion transmitted
diseases. Reveal and Multiplo will also prove valuable in public
healthcare initiatives as well as disaster and humanitarian relief
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The Company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for infectious diseases in
just three minutes. MedMira tests are sold under the Reveal®, Multiplo™
and Miriad brands in global markets. MedMira's rapid flow-through HIV
test is the only one in the world to achieve regulatory approvals in
Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in Halifax,
Nova Scotia, Canada. For more information visit www.medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
approval and launch of new products, future growth, and new business
opportunities. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications